

Emergent BioSolutions (NYSE:EBS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been...
You can purchase shares of Emergent BioSolutions (NYSE:EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Emergent BioSolutions has a consensus price target of $13.50.
The stock price for Emergent BioSolutions (NYSE: EBS) is $5.81 last updated November 16, 2026 at 7:00 PM EST.
There are no upcoming dividends for Emergent BioSolutions.
Emergent BioSolutions does not have any upcoming earnings scheduled.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.